CPC C07K 16/1271 (2013.01) [A61K 39/40 (2013.01); A61K 45/06 (2013.01); A61K 49/00 (2013.01); C07K 14/31 (2013.01); C07K 16/1214 (2013.01); C07K 16/1228 (2013.01); C07K 16/1242 (2013.01); C07K 16/1275 (2013.01); C12Q 1/18 (2013.01); G01N 33/566 (2013.01); G01N 33/56911 (2013.01); A61K 35/12 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C12N 15/86 (2013.01); G01N 2333/195 (2013.01); G01N 2333/21 (2013.01); G01N 2333/245 (2013.01); G01N 2333/26 (2013.01); G01N 2333/285 (2013.01); G01N 2469/10 (2013.01)] | 18 Claims |
1. A monoclonal antibody (mAb) or antigen binding fragment thereof that specifically binds a DNA binding protein II (DNABII), wherein the mAb or antigen binding fragment thereof comprises:
a heavy chain variable region (SEQ ID NO:1) and a light chain variable region (SEQ ID NO: 2) of TRL1068;
a heavy chain variable region (SEQ ID NO:21) and a light chain variable region (SEQ ID NO: 22) of TRL1330; or,
a heavy chain variable region (SEQ ID NO:25) and a light chain variable region (SEQ ID NO: 26) of TRL1337.
|